Icatibant
Icatibant is a bradykinin B2 receptor antagonist used for the treatment of acute hereditary angioedema (HAE) attacks in adults with C1-esterase-inhibitor deficiency. By blocking bradykinin, it reduces the vascular permeability and swelling characteristic of HAE attacks.
Icatibant is a bradykinin B2 receptor antagonist used to treat acute attacks of hereditary angioedema in adults.
Key facts at a glance
- ATC
- B06AC02
- RxNorm
- 1148138
- Generic
- Icatibant
- Class
- atc-b06
- Brands
- Firazyr, Sajazir
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 30mg
- Maximum
- consult physician
- Frequency
- every 6 hours as needed
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 0.3mg/kg (maximum 30mg)
- Maximum
- consult physician
- Frequency
- every 6 hours as needed
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 30mg
- Maximum
- consult physician
- Frequency
- every 6 hours as needed
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
11 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
second trimesteruse only if benefits outweigh risks
use only if acute attack is severe and benefits justify potential risk
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteruse only if benefits outweigh risks
use only if acute attack is severe and no safer alternative available
regular fetal monitoring and uterine activity monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedinguse with caution
breastfeeding not recommended during treatment or for 12 hours after administration
monitor infant for adverse effects
geriatric
elderlyno dose adjustment required
use standard adult dosing, monitor renal and hepatic function
monitor renal and hepatic function regularly
pediatric_age
adolescents 12 17 yearsweight-based dosing
30 mg for body weight ≥ 40 kg; 1 mg/kg for body weight < 40 kg
monitor response and adverse effects
pediatric_age
children 2 11 yearsweight-based dosing required
1 mg/kg body weight subcutaneously, maximum 30 mg
close monitoring of response and adverse effects
renal_impairment
mild to moderateno dose adjustment required
standard dosing can be used
no specific monitoring required
renal_impairment
severeuse with caution
use standard dosing but monitor closely
monitor renal function
Use with caution and monitor for adverse effects.
hepatic_impairment
mild to moderateno dose adjustment required
standard dosing can be used
no specific monitoring required
hepatic_impairment
severeuse with caution
use standard dosing but monitor closely
monitor hepatic function
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Pharmacological classification of Icatibant
FDA approval
FDA approval year for hereditary angioedema treatment
Primary indication
Main therapeutic indication for Icatibant
Route of administration
Method of drug administration
Treatment of acute hereditary angioedema (HAE) attacks in adults and adolescents (≥12 years) with C1-esterase-inhibitor deficiency. It is used for attacks affecting the skin, face, abdomen, or larynx.
Icatibant is a selective competitive antagonist at the bradykinin B2 receptor. It blocks bradykinin from binding to its receptor, preventing the increase in vascular permeability and subsequent tissue swelling that occurs during HAE attacks.
Administered as a subcutaneous injection (typically 30 mg). May cause local injection site reactions (redness, swelling, burning). Should be used with caution in patients with cardiovascular disease. Not for use in children under 12 years. Patients should seek immediate medical attention for laryngeal attacks as this is a medical emergency.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy